159 related articles for article (PubMed ID: 30745553)
1. [Severe interstitial lung disease after one cycle of nivolumab treatment in a patient with advanced gastric cancer].
Shimada S; Ando T; Yokota T; Sakumura M; Yoshita H; Nanjo S; Mihara H; Kajiura S; Fujinami H; Yasuda I
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(2):153-160. PubMed ID: 30745553
[TBL] [Abstract][Full Text] [Related]
2. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
Saito Y; Sasaki S; Oikado K; Tominaga J; Sata M; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1495-1505. PubMed ID: 33098725
[TBL] [Abstract][Full Text] [Related]
3. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
[TBL] [Abstract][Full Text] [Related]
4. Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis.
Kashiwada T; Minegishi Y; Saito Y; Kato T; Atsumi K; Seike M; Kubota K; Terasaki Y; Gemma A
J Nippon Med Sch; 2019; 86(1):43-47. PubMed ID: 30918156
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer.
Nakatani Y; Kawakami H; Ichikawa M; Yamamoto S; Otsuka Y; Mashiko A; Takashima Y; Ito A; Nakagawa K; Arima S
Invest New Drugs; 2018 Aug; 36(4):726-731. PubMed ID: 29623482
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced anti-aminoacyl-tRNA synthetase antibody-positive polymyositis complicated by interstitial pneumonia in a patient with lung adenocarcinoma.
Shikano K; Kaneko K; Kaburaki K; Isobe K; Kawabe K; Homma S; Kawai S; Nanki T
Scand J Rheumatol; 2020 Jan; 49(1):82-83. PubMed ID: 31135242
[No Abstract] [Full Text] [Related]
8. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: A case report.
Tanabe K; Kanzaki H; Wada T; Nakashima Y; Sugiyama H; Okada H; Wada J
Medicine (Baltimore); 2020 May; 99(21):e20464. PubMed ID: 32481351
[TBL] [Abstract][Full Text] [Related]
10. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis.
Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Hanai N; Muro K; Hida T
BMC Cancer; 2021 Aug; 21(1):924. PubMed ID: 34399710
[TBL] [Abstract][Full Text] [Related]
11. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP).
Ishiwata T; Ebata T; Iwasawa S; Matsushima J; Ota S; Nakatani Y; Tsushima K; Tada Y; Tatsumi K; Takiguchi Y
Intern Med; 2017 Sep; 56(17):2311-2315. PubMed ID: 28794361
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma.
Tokumo K; Masuda T; Miyama T; Miura S; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Yoshida T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Lung Cancer; 2018 May; 119():21-24. PubMed ID: 29656748
[TBL] [Abstract][Full Text] [Related]
14. Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.
Baba T; Sakai F; Kato T; Kusumoto M; Kenmotsu H; Sugiura H; Tominaga J; Oikado K; Sata M; Endo M; Yanagawa N; Sasaki S; Iwasawa T; Saito Y; Fujiwara Y; Ohe Y; Yamazaki N; Sakamoto T; Koshiba T; Kuwano K
Future Oncol; 2019 Jun; 15(16):1911-1920. PubMed ID: 31020849
[No Abstract] [Full Text] [Related]
15. DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer.
Sunakawa Y; Inoue E; Matoba R; Kawakami H; Sato Y; Nakajima TE; Muro K; Ichikawa W; Fujii M
Future Oncol; 2019 Jul; 15(21):2441-2447. PubMed ID: 31140303
[No Abstract] [Full Text] [Related]
16. [Clinical Evaluation of the Efficacy and Adverse Effects of Nivolumab Treatment for Patients with Advanced Gastric Cancer].
Ohta A; Komatsu S; Tsuji R; Tanaka S; Kumano T; Imura K; Shimomura K; Ikeda J; Taniguchi F; Doi T; Yamada S; Tomatsuri N; Yoshida N; Shioaki Y
Gan To Kagaku Ryoho; 2020 Apr; 47(4):725-727. PubMed ID: 32389997
[TBL] [Abstract][Full Text] [Related]
17. A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy.
Satoyoshi R; Muto O; Masuda A; Kotanagi K; Kichiraku T; Kudoh K; Sawada T; Miyazawa H; Kotanagi H
Clin J Gastroenterol; 2019 Feb; 12(1):15-19. PubMed ID: 30206777
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
19. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.
Namikawa T; Yokota K; Tanioka N; Fukudome I; Iwabu J; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Surg Today; 2020 Nov; 50(11):1486-1495. PubMed ID: 32542414
[TBL] [Abstract][Full Text] [Related]
20. Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review of the Literature.
Manapov F; Roengvoraphoj O; Dantes M; Marschner S; Li M; Eze C
J Immunother; 2018; 41(2):96-99. PubMed ID: 29200082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
